Click here for seasoned global CorpDev/ M&A/ PE expertise on demand In a landmark move reshaping the rare disease therapeutics landscape, BioMarin Pharmaceutical announced its $270 million...
Click here for seasoned global CorpDev/ M&A/ PE expertise on demand In a dramatic twist to one of 2025's most consequential REIT mergers, Primary Health Properties (LSE: PHP) has launched a £1.68...
Click here for seasoned global CorpDev/ M&A/ PE expertise on demand Deal Snapshot: 23andMe Acquisition AcquirerRegeneron Pharmaceuticals Target23andMe (excl. Lemonaid Health) Price$256M (92% below...
Click here for seasoned global CorpDev/ M&A/ PE expertise on demand In a dual strategic move reshaping the digital health landscape, London-based healthtech unicorn Huma Therapeutics has acquired...
Click here for seasoned global CorpDev/ M&A/ PE expertise on demand In a strategic move to consolidate its leadership in the rapidly expanding obesity drug market, Novo Nordisk announced a landmark...
Click here for seasoned global CorpDev/ M&A/ PE expertise on demand In a bold move to secure leadership in the rapidly evolving hepatology sector, GSK announced a $2 billion acquisition of Boston...
Click here for seasoned global CorpDev/ M&A/ PE expertise on demand Deal at a Glance ⚖️ Valuation: $10B+ enterprise value 📈 Key Growth Driver: 78% CAGR in GLP-1 drug packaging since 2022 🩺...
HistoSonics, the Johnson & Johnson-backed pioneer of histotripsy technology, stands at the center of a high-stakes acquisition battle that could redefine tumor treatment paradigms. With Medtronic,...
In a move signaling renewed aggression in pharmaceutical M&A, Germany's Merck KGaA stands poised to finalize its largest therapeutic acquisition in a decade with the $3.5 billion purchase of...
As global trade tensions escalate under the Trump administration's tariff policies, Roche AG has emerged as a pivotal player in reshaping pharmaceutical manufacturing strategies. The Basel-based...
